Nabil M. Ahmed, MD
Brain tumors, Bone tumors, Ewing Sarcoma, BMT/SCT
Dr. Nabil Ahmed is a physician-scientist engaged in translational research to improve therapy for brain tumors, focusing on adoptive immunotherapy with gene-modified effector cells.
Malcolm K. Brenner, MD, PhD
BMT/SCT, Brain tumors, Lymphoma, Neuroblastoma
Dr. Malcolm Brenner's primary research interest is the use of gene transfer to augment the immune response to human tumors, using vaccines and adoptive transfer of genetically modified T cells.
Andras A. Heczey, MD
BMT/SCT, Liver tumors, Neuroblastoma, Solid tumors
Dr. Andras Heczey's research focuses on developing novel treatments for children with solid tumors by redirecting the immune system to kill cancer cells using genetically engineered T cells and natural killer T cells.
Meenakshi G. Hegde, MD
BMT/SCT, Brain tumors, Bone tumors, Ewing sarcoma, Solid tumors
Dr. Meenakshi Hegde’s research focuses on developing novel treatments for children with brain and solid tumors. She uses engineered T-cells equipped to overcome the inhibitory tumor environment to effectively target these tumors.
Dr. Helen Heslop is a physician-scientist engaged in translational research focusing on adoptive immunotherapy with gene-modified and virus-specific effector cells to improve outcomes in hematologic malignancies and in the post-stem cell transplant setting.
Ann M. Leen, PhD
Dr. Ann Leen’s research interests involve using cytotoxic T cells for the prophylaxis and treatment of virus-associated malignancies.
Maksim Mamonkin, PhD
Dr. Maksim Mamonkin’s lab focuses on creating novel chimeric antigen receptors to target intractable diseases, specifically hematologic malignancies of T-cell origin.
Leonid S. Metelitsa, MD, PhD
Dr. Leonid Metelitsa’s research focuses on understanding the role of natural killer T cells in tumor immunity and translating this knowledge into cell-based cancer immunotherapies.
Bilal A. Omer, MD
Dr. Bilal Omer is focused on developing T cell products to combat viral infections following hematopoietic stem cell transplantation, one of the leading causes of morbidity and mortality in children, as well as novel cell therapies to target pediatric solid and hematological malignancies.
Robin Parihar, MD, PhD
Solid tumors, Neuroblastoma
Dr. Robin Parihar investigates the role of natural killer cells in order to enhance their ability to target the tumor microenvironment, essentially getting rid of accessory cells that help a tumor resist standard therapies.
Carlos A. Ramos, MD
Dr. Carlos Ramos leads clinical investigations of multiple genetically-engineered cell therapy products to treat cancer, including CD19-targeting T cells and natural killer T cells, among other treatments.
Cliona Rooney, PhD
BMT/SCT, Lymphoma, Solid tumors
Dr. Cliona Rooney’s research interests are immunotherapies for virus and non-virus-associated malignancies and diseases.
Rayne H. Rouce, MD
BMT/SCT, Leukemia, Lymphoma
Dr. Rayne Rouce’s translational research is informed by her clinical interests in high-risk and refractory leukemia and lymphoma. She leads clinical investigations of genetically-engineered and virus-specific cell therapies for refractory hematologic malignancies, while also translating novel cell therapy products tackling the two main causes of morbidity and mortality following hematopoietic stem cell transplant: viral infection and relapse.